Proteomics for the study of new biomarkers in Fabry disease: State of the art.
Anderson-Fabry disease
Biomarkers
Clinical proteomics
Fabry nephropathy
Mass spectrometry
Matrix-assisted laser desorption/ionization
Journal
Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
05
08
2020
revised:
08
10
2020
accepted:
11
10
2020
pubmed:
21
10
2020
medline:
10
8
2021
entrez:
20
10
2020
Statut:
ppublish
Résumé
Nephropathy represents a major complication of Fabry Disease and its accurate characterization is of paramount importance in predicting the disease progression and assessing the therapeutic responses. The diagnostic process still relies on performing renal biopsy, nevertheless many efforts have been made to discover early reliable biomarkers allowing us to avoid invasive procedures. In this field, proteomics offers a sensitive and fast method leading to an accurate detection of specific pathological proteins and the discovery of diagnostic and prognostic biomarkers that reflect disease progression and facilitate the evaluation of therapeutic responses. Here, we report a review of selected literature focusing on the investigation of several proteomic techniques highlighting their advantages, limitations and future perspectives in their application in the routine study of Fabry Nephropathy.
Identifiants
pubmed: 33077353
pii: S1096-7192(20)30206-7
doi: 10.1016/j.ymgme.2020.10.006
pii:
doi:
Substances chimiques
Biomarkers
0
Proteins
0
Proteome
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-93Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest H.P.M. reports receiving grants from Alexion, Amicus, Sanofi Genzyme, and Shire. E.S. reports receiving grants from Sanofi Genzyme; positions on the advisory boards of Amicus and Sanofi Genzyme; speaker fees and travel support from Amicus, Sanofi Genzyme, and Shire-Takeda. F.Pi. reports participation at advisory boards, speaker fees and travel support from Amicus, Sanofi Genzyme, and Shire-Takeda. F.R., V.L., A.S., M.M.B., F.M. and F.Pa. declare no conflict of interest.